John Amako: Childhood to Adulthood Management Approach for SCD
John Amako, Branch Manager at United Healthcare International Ltd., shared on LinkedIn:
”Childhood to Adulthood Management approach for Sickle Cell Disease;
Managing Sickle Cell Disease (SCD) involves lifelong care, starting with infancy (antibiotics, hydroxyurea, vaccinations) to prevent infections and crises, progressing through childhood (stroke screening, education for self-advocacy) and adolescence, with a critical transition to adult care focusing on managing complex comorbidities, chronic pain, and self-management, with treatments like hydroxyurea, transfusions, pain management, lifestyle changes, and newer gene therapies offering potential cures, all under a specialized healthcare team.
Childhood Management (Infancy to Adolescence):
- Infection Prevention: Daily penicillin until age 5, vaccinations, and prompt attention to fever.
- Hydroxyurea: Often started early (around 9 months) to reduce pain crises, acute chest syndrome, and hospitalizations, increasing fetal hemoglobin.
- Stroke Prevention: Annual Transcranial Doppler (TCD) ultrasounds from ages 2-16; if abnormal, chronic transfusions or hydroxyurea may be used.
- Pain Management: Home management for mild pain (hydration, OTC meds) and prompt care for severe pain.
- Education: Teaching children and families about triggers (cold, dehydration) and self-care.
Transition to Adulthood
– Self-Advocacy: Crucial stage where young people learn to manage their own care, transitioning from pediatric to adult hematology teams.
– Increased Complexity: Adults face more organ damage, chronic pain, and psychosocial challenges.
– Healthcare System Gaps: A known risk period for poor outcomes due to fragmented care.
Adult Management and Lifelong Care
Medications:
Hydroxyurea: Still a cornerstone for preventing crises, improving anemia.
L-glutamine (Endari): Reduces pain crises in patients 5+.
Crizanlizumab (Adakveo): Injection to reduce pain crises in those 16+.
Folic Acid: Daily supplementation to support red blood cell production.
Transfusions: Regular chronic transfusions or emergency transfusions for severe complications.
Pain Management: Multimodal approach, including opioids for severe pain, avoiding certain drugs like meperidine (Demerol).
Lifestyle: Stay hydrated, stay warm, avoid extreme temperatures, and manage stress.
Curative Options:
- Stem Cell Transplant: Potential cure, but carries risks and requires donors.
- Gene Therapies (e.g., Casgevy, Lyfgenia): Newly approved for patients 12+.
Key Principles Across Lifespan
- Specialized Team: Care by hematologists, nurses, social workers, and psychologists.
- Patient Education: Essential for managing triggers and understanding treatment.
- Early Intervention: Prompt treatment for acute issues like chest syndrome, stroke, or severe pain.”

Stay updated with Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026